Page 39 - Read Online

Page 4 of 7 Im et al. Vessel Plus 2018;2:5 I http://dx.doi.org/10.20517/2574-1209.2018.07

Table 2. The 10-year CVD risk and aspirin use
Total (n = 1125) Men (n = 764) Women (n = 361)
10-year CVD risk (%) 0.5-46.2 1.4-46.2 0.5-20.2
≥ 10% 10-year CVD risk 266 (23.6) 253 (33.1) 13 (3.6)
Current aspirin use 44 (3.9) 34 (4.5) 10 (2.8)
Appropriate 16 (36) 15 (44) 1 (10)
Inappropriate 28 (64) 19 (56) 9 (90)
Data are numbers (%). CVD: cardiovascular disease

Table 3. The 10-year CVD risk and aspirin use according to gender and age
Men Women
Total 50-59 years 60-69 years Total 50-59 years 60-69 years
(n = 764) (n = 583) (n = 181) (n = 361) (n = 229) (n = 132)
10-year CVD risk (%) 1.4-46.2 1.4-25.8 4.3-46.2 0.5-20.2 0.5-8 1.8-20.2
≥ 10% 10-year CVD risk 253 (33.1) 117 (20.1) 136 (75.1) 13 (3.6) 0 (0) 13 (9.8)
Current aspirin use 34 (4.5) 20 (3.4) 14 (7.7) 10 (2.8) 4 (1.7) 6 (4.5)
Appropriate 15 (44) 5 (25) 10 (71) 1 (10) 0 (0) 0 (0)
Inappropriate 19 (56) 15 (75) 4 (29) 9 (90) 4 (100) 6 (100)
Data are numbers (%). CVD: cardiovascular disease

Figure 1. The 10-year cardiovascular disease (CVD) risk and the aspirin use according to gender and age

Table 4 shows the relationship between the factors of ASCVD risk calculation and taking aspirin. Treatment
for hypertension was significantly associated with taking aspirin [odd ratio (OR) 7.49; 95% confidence
interval (CI) 3.62-15.49]. Though there were no significant differences, a trend toward taking aspirin was
related with age (OR 1.02; 95% CI 0.99-1.12) and men (OR 1.64; 95% CI 0.79-3.35). Smoking was inversely
related with aspirin use (OR 0.59; 95% CI 0.24-1.42). Of the 1125 participants, 265 (23.6%) underwent IMT
measurements. The mean IMT was significantly greater in the ≥ 10% 10-year CVD risk group (n = 70, 0.83 ±
0.13 mm) than in the < 10% 10-year CVD risk group (n = 195, 0.78 ± 0.12 mm; P = 0.003).